Clinical Trials
47 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
I-SPY
QuantumLeap Healthcare Collaborative
DOSa
M.D. Anderson Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
ANGIO-TAX+
Centre Oscar Lambret
TAIS
Fudan University
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Massachusetts General Hospital
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
TTI-621-03
Pfizer
Cemiplimab for Secondary Angiosarcomas
Radboud University Medical Center
Propranolol in Angiosarcoma
The Netherlands Cancer Institute
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
PROPANE
Herlev and Gentofte Hospital
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
EVA
Heidelberg University
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
National Cancer Institute (NCI)
ASAP
Dong-A University Hospital
Bevacizumab in Treating Patients With Angiosarcoma
Northwestern University
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Stanford University
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
UNICANCER
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
National Cancer Institute (NCI)
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
National Cancer Institute (NCI)
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Daiichi Sankyo
Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery
National Cancer Institute (NCI)